Levobupivacaína Kabi (Levobupivacaine Hydrochloride)

Levobupivacaine blocks voltage‑gated sodium channels on nerve membranes, stabilizing them in an inactive state. This prevents the rapid influx of sodium ions needed for depolarization, thereby inhibiting the generation and propagation of nerve impulses. The result is a reversible loss of sensation in the area where the drug is applied.

The specific dose of Levobupivacaína Kabi is determined by the prescribing clinician based on the type of procedure, patient characteristics, and the chosen route of administration. Dosage calculations consider factors such as total allowable dose, concentration of the solution, and the need for incremental injection.

Safety data for levobupivacaine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Use during pregnancy or while breastfeeding should only occur if the potential benefit justifies any potential risk, and it must be decided by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials. After verification, the team provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Levobupivacaine is the S‑enantiomer of bupivacaine and offers a similar duration of anesthesia with a lower risk of cardiotoxicity and central nervous system toxicity. Both agents provide long‑lasting analgesia, but levobupivacaine is often preferred when a safer cardiac profile is desired, especially in high‑risk patients.

Levobupivacaína Kabi should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations. Do not freeze the solution, and ensure the container is sealed when not in use.

The drug is supplied as a sterile solution for injection. It can be administered via epidural, intrathecal, infiltration, or peripheral nerve techniques. Administration is performed by trained anesthesiologists or qualified clinicians who follow aseptic technique, aspirate to avoid intravascular injection, and monitor the patient throughout the procedure.

Serious risks include cardiovascular toxicity such as hypotension, bradycardia, arrhythmias, and cardiac arrest, as well as central nervous system toxicity leading to seizures or respiratory depression. Rare but severe reactions may involve allergic responses, methemoglobinemia, and persistent neurologic deficits. Immediate monitoring and prompt management are essential.

Levobupivacaína Kabi should be avoided in patients with known hypersensitivity to levobupivacaine or other amide local anesthetics. Caution is advised for individuals with severe cardiac disease, significant hepatic impairment, or those receiving interacting medications that increase the risk of toxicity. The decision to use the drug must be made by a qualified healthcare professional.